Compare · LNTH vs ORKA
LNTH vs ORKA
Side-by-side comparison of Lantheus Holdings Inc. (LNTH) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LNTH and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LNTH is the larger of the two at $6.90B, about 1.4x ORKA ($5.03B).
- ORKA has been more active in the news (14 items in the past 4 weeks vs 4 for LNTH).
- LNTH has more recent analyst coverage (17 ratings vs 11 for ORKA).
- Company
- Lantheus Holdings Inc.
- Oruka Therapeutics Inc.
- Price
- -
- -
- Market cap
- $6.90B
- $5.03B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 4
- 14
- Recent ratings
- 17
- 11
Lantheus Holdings Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Latest LNTH
- Director Ber Gerard covered exercise/tax liability with 381 shares, decreasing direct ownership by 1% to 27,118 units (SEC Form 4)
- Executive Chair and CEO Heino Mary Anne covered exercise/tax liability with 1,227 shares, decreasing direct ownership by 0.38% to 321,897 units (SEC Form 4)
- Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI's Image of the Year
- SEC Form SD filed by Lantheus Holdings Inc.
- Lantheus to Present at the William Blair 46th Annual Growth Stock Conference
- Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting
- Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
- Director Mchugh Julie was granted 4,137 shares, increasing direct ownership by 16% to 30,099 units (SEC Form 4)
- Director Morrow Phuong Khanh was granted 4,137 shares, increasing direct ownership by 133% to 7,237 units (SEC Form 4)
Latest ORKA
- Senior Vice President, Finance Agarwal Arjun sold $128,468 worth of shares (1,587 units at $80.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 15,312 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,459 shares at a strike of $15.88 and sold $687,035 worth of shares (9,854 units at $69.72) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 16,899 units (SEC Form 4) to cover taxes
- Chief Medical Officer Goncalves Joana sold $550,607 worth of shares (7,947 units at $69.28) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $7.32, decreasing direct ownership by 3% to 32,718 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Klein Lawrence Otto sold $120,494 worth of shares (1,729 units at $69.69), decreasing direct ownership by 0.19% to 925,580 units (SEC Form 4) to cover taxes
- Chief Operating Officer Sandler Laura Lee sold $41,814 worth of shares (600 units at $69.69), decreasing direct ownership by 0.25% to 236,384 units (SEC Form 4) (for tax liability)
- General Counsel Quinlan Paul T sold $51,083 worth of shares (733 units at $69.69), decreasing direct ownership by 2% to 31,034 units (SEC Form 4) (for withholding tax)
- Director Dambkowski Carl sold $2,454,382 worth of shares (35,000 units at $70.13) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 38,743 units (SEC Form 4)
- Oruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Dambkowski Carl
- SEC Form 4 filed by Director Kulkarni Samarth